Tello VA, Hernández BV, Durán MC, Berrón PR

Language: Spanish
References: 11
Page: 25-27
PDF size: 136.86 Kb.

ABSTRACT

Pyoderma gangrenosum is a disease characterized by the appearance of cutaneous of fast growth, painful ulcers of raised edges, necrotic center, exudates purulent, of unknow etiology. Its presentation is little frequent in the pediatric age. We reported the case of a girl patient of 6 years with pyoderma gangrenosum and she received intravenous immunoglobulin (400 mg/kg) and prednisona to 0.5 mg/kg. She was followed during 21 months. We observed immediate halting in the growth of the ulcers with tendency to the improvement of the injuries, without relapses of new injuries.

REFERENCES

1. Peter i. Long hypoderma gangrenosum. JAMA 1964; 187: 336-33.

2. Brunssting LA. Pyoderma gangrenosum. Arch of Derm Syphilology 1930: 656-80.

3. Bennet ML, Mark JJ. Pyoderma gangrenosum: a comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Lippincott Williams & Wilkins, Inc 2000; 79: 37-46.

4. Robert KP. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996; 34: 1047-60.

5. Radomsky C. Thalidomide. Dermatol Clin 2001; 19(1): 87-103.

6. Dínca R. Tacrolimus to treat pyoderma gangrenosum resistant to cyclosporine. Annals of Internal Medicine 1998; 128: 783-4.

7. Federman G. Recalcitrant pyoderma gangrenosum treated with thalidomide. Mayo Clin Proc 2000; 75: 824-44.

8. Ruiz MR, Berrón PR, Durán MC. Pioderma gangrenosum in children. Report of eight cases and review of the literature. Eur J Dermatol 1994; 4: 514-20.

9. Powell F. Pyoderma gangrenosus: classification and management. J Am Acad Dermatol 1996; 34: 395-409.

10. Colsky A. Intravenous immunoglobulin in autoimmune and inflammatory dermatoses. A review of proposed mechanisms of action and therapeutic applications. Dermatol Clin 2000; 18: 447-57.

11. Weber S. Ecthyma gangrenosum and Pseudomonas aeruginosa. Harvard Medical center, 2001. Communication preliminary.